Vericel’s Q1 Revenue Jumps 30% to $68.4M, Guidance Raised to $336M
Vericel’s first-quarter revenue climbed 30% year-over-year to $68.4 million, driven by 22% MACI growth to $56.4 million and a 91% surge in burn care sales to $12.0 million. The company raised its full-year 2026 revenue outlook by $10 million to a range of $326–$336 million.
1. First Quarter Financial Performance
Vericel posted $68.4 million in net revenue for Q1 2026, up 30% from a year earlier. MACI sales grew 22% to $56.4 million while burn care revenue soared 91% to $12.0 million. Gross margin reached 72% and adjusted EBITDA increased 195% to $9.6 million.
2. Business Developments
Epicel revenue surged 119% and record quarterly biopsies and implants drove MACI adoption. The company secured a BARDA award valued at up to $197 million for NexoBrid procurement and advanced development, received FDA approval for commercial MACI manufacturing at its new facility, and plans a UK marketing application submission in 2026.
3. Updated 2026 Guidance
Vericel raised full-year revenue guidance by $10 million to $326–$336 million, with MACI revenue expected at $282–$288 million and burn care at $44–$48 million. The company reaffirmed targets of approximately 75% gross margin and 27% adjusted EBITDA margin.